Guideline for PET/CT Imaging of Neuroendocrine Neoplasms with 68Ga-DOTA-conjugated Somatostatin Receptor Targeting Peptides
Journal Title: Nuclear Medicine Seminars - Year 2020, Vol 6, Issue 3
Abstract
Neuroendocrine tumors (NETs) are one of the rare cancers that have been increasing in recent years. The importance of Ga-68 DOTA-Conjugated Peptides Receptor imaging has been reported in many retrospective and prospective studies in the diagnosis and clinical management of NETs. Three different somatostatin analogues labeled Ga-68 are used in clinical practice. The most commonly used Ga-68 DOTA-Conjugated Peptides are DOTA-D-Phe-Tyr3-octreotide (DOTA-TOC), DOTA-1-NaI (3)- octreotide (DOTA-NOC) and DOTA-D-Phe-Tyr3-octreotate (DOTA-TATE) in rutin. Although all these radiopeptides bind to sst-r 2, each has different affinity profiles for other sst-r subtypes. Performed related studies have shown that the compound with the highest affinity for somatostatin receptor 2 (sst-r 2), which is most frequently expressed in NETs, is DOTA-TATE. Ga-68 DOTA-bound somatostatin receptor (sst-r) PET/CT is used in the preoperative staging of NETs, determination of treatment response, restaging, showing somatostatin receptor uptake before peptide receptor radionuclide treatment. This guideline, mainly for nuclear medicine physicians contains recommendations in terms of procedure, reporting and interpretation in order to standardize Ga-68 DOTA conjugated peptid PET/CT imaging in NETs.
Authors and Affiliations
Nalan Alan Selçuk, Emre Demirci, Levent Kabasakal, Gülin Uçmak, Umut Elboğa, Cüneyt Türkmen, İlknur Ak Sivrikoz
Keywords
Related Articles
- EP ID EP691581
- DOI 10.4274/nts.galenos.2020.0032
- Views 108
- Downloads 0
F-18 FDG PET/CT Practice Guideline in Oncology
Positron emission tomography (PET) is a tomographic imaging method that shows three-dimensional distribution of radiopharmaceuticals which are labelled with positron emitter radionuclides. Today most widely used PET radi...
Early and Late Side Effects and Patient Management in I-131 Treatment
I-131 is the first most experienced theranostic radionuclide that has been used since the early 1940s for the treatment of hyperthyroidism, metastases or ablation of residual thyroid tissue in well-differentiated thyroid...
Guideline for PET/CT Imaging of Neuroendocrine Neoplasms with 68Ga-DOTA-conjugated Somatostatin Receptor Targeting Peptides
Neuroendocrine tumors (NETs) are one of the rare cancers that have been increasing in recent years. The importance of Ga-68 DOTA-Conjugated Peptides Receptor imaging has been reported in many retrospective and prospectiv...
Developments in Pain Imaging
In order to determine the etiology of chronic pain, radiological imaging tools like computed tomography (CT) and magnetic resonance imaging (MRI) are usually used. Except for the anatomical data that the radiological ima...
Practical Guidance on Peptide Receptor Radionuclide Therapy
Peptide receptor radionuclide therapy (PRRT) have been successfully used for the past 20 years to target metastatic or inoperable neuroendocrine tumors expressing the somatostatin receptors. Both prospective and retrospe...